These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26436085)

  • 1. Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice.
    Ma H; Mallampati S; An G; Wang J
    Biomed Res Int; 2015; 2015():157570. PubMed ID: 26436085
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chemotherapy in elderly patients with hematological malignancies].
    Ohnishi K
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1586-90. PubMed ID: 21996952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A role of new molecular-target drugs for hematologic malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2015 May; 42(5):548-9. PubMed ID: 26054087
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hematologic malignancies/pediatric malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies.
    Xie L; Jing R; Qi J; Lin Z; Ju S
    Blood Rev; 2015 Jan; 29(1):33-44. PubMed ID: 25263425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alpha2 in the treatment of hematological malignancies. Status and perspectives.
    Hasselbalch HC
    Curr Drug Targets; 2011 Mar; 12(3):387-91. PubMed ID: 21143152
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
    Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
    Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Empirical Study of the Prescription Pattern of Drugs for Hematological Malignancies in Japan from 2010-2014.
    Shibata S; Wayama Y; Tsuyuki A; Matsushita M; Chiba K; Matsuki E; Okamoto S; Suzuki T
    Biol Pharm Bull; 2017; 40(6):894-901. PubMed ID: 28566631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPHA3 as a novel therapeutic target in the hematological malignancies.
    Keane N; Freeman C; Swords R; Giles FJ
    Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecularly target therapy].
    Kiyoi H
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():211-6. PubMed ID: 23133955
    [No Abstract]   [Full Text] [Related]  

  • 11. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
    Bryan LJ; Gordon LI
    Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
    Ravandi F; Talpaz M; Estrov Z
    Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of vitamin D and derivatives in hematological malignancies.
    Kim M; Mirandola L; Pandey A; Nguyen DD; Jenkins MR; Turcel M; Cobos E; Chiriva-Internati M
    Cancer Lett; 2012 Jun; 319(1):8-22. PubMed ID: 22193723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.
    Wright J; Hillsamer VL; Gore-Langton RE; Cheson BD
    Oncology (Williston Park); 2000 Nov; 14(11):1589-90, 1593-4, 1597. PubMed ID: 11125942
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
    Usui N
    Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
    [No Abstract]   [Full Text] [Related]  

  • 16. Farnesyl transferase inhibition in hematologic malignancies.
    Karp JE
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S37-40. PubMed ID: 16280111
    [No Abstract]   [Full Text] [Related]  

  • 17. Investigational antibody-drug conjugates for hematological malignancies.
    Polson AG; Ho WY; Ramakrishnan V
    Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?
    Cierpicki T; Grembecka J
    Immunol Rev; 2015 Jan; 263(1):279-301. PubMed ID: 25510283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies.
    Roberts AW; Stevenson FK
    Blood; 2021 Sep; 138(13):1089. PubMed ID: 34320159
    [No Abstract]   [Full Text] [Related]  

  • 20. American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
    Tear S
    IDrugs; 2007 Feb; 10(2):84-6. PubMed ID: 17285454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.